NO963726D0 - Sammensetninger for inhibisjon av TNF-dannelse og anvendelser derav - Google Patents

Sammensetninger for inhibisjon av TNF-dannelse og anvendelser derav

Info

Publication number
NO963726D0
NO963726D0 NO963726A NO963726A NO963726D0 NO 963726 D0 NO963726 D0 NO 963726D0 NO 963726 A NO963726 A NO 963726A NO 963726 A NO963726 A NO 963726A NO 963726 D0 NO963726 D0 NO 963726D0
Authority
NO
Norway
Prior art keywords
inhibition
compositions
applications
tnf formation
tnf
Prior art date
Application number
NO963726A
Other languages
English (en)
Other versions
NO963726L (no
Inventor
Robert F Halenback
Michael Kriegler
Carl Perez
David A Jewell
Kriston E Koths
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/230,428 external-priority patent/US5998378A/en
Priority claimed from US08/394,600 external-priority patent/US5843693A/en
Priority claimed from US08/395,456 external-priority patent/US6586222B1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO963726D0 publication Critical patent/NO963726D0/no
Publication of NO963726L publication Critical patent/NO963726L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO963726A 1994-03-07 1996-09-06 Sammensetninger for inhibisjon av TNF-dannelse og anvendelser derav NO963726L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20857494A 1994-03-07 1994-03-07
US08/230,428 US5998378A (en) 1989-08-16 1994-04-19 Compositions for the inhibition of TNF hormone formation and uses thereof
US08/394,600 US5843693A (en) 1989-08-16 1995-02-27 Assay method for screening for inhibitors of proTNF conversion
US08/395,456 US6586222B1 (en) 1989-08-16 1995-02-28 Recombinant PR-3 and compositions thereof
PCT/US1995/002513 WO1995024501A1 (en) 1994-03-07 1995-03-02 Compositions for the inhibition of tnf formation and uses thereof

Publications (2)

Publication Number Publication Date
NO963726D0 true NO963726D0 (no) 1996-09-06
NO963726L NO963726L (no) 1996-10-31

Family

ID=27498725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963726A NO963726L (no) 1994-03-07 1996-09-06 Sammensetninger for inhibisjon av TNF-dannelse og anvendelser derav

Country Status (7)

Country Link
US (1) US6599706B1 (no)
EP (1) EP0749494A1 (no)
JP (1) JPH10504441A (no)
AU (1) AU709054B2 (no)
CA (1) CA2185162A1 (no)
NO (1) NO963726L (no)
WO (1) WO1995024501A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752369B2 (en) * 1995-06-08 2002-09-19 Immunex Corporation TNF-alpha converting enzyme
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
NZ312285A (en) * 1995-06-08 2001-04-27 Immunex Corp TNF-alpha converting enzyme (TACE)
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase
EP0912746A2 (en) * 1996-07-12 1999-05-06 Schering Corporation MAMMALIAN TNF-$g(a) CONVERTASES
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
DE19726248C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Behandlung von septischem Schock
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
CA2596537A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
DE102009009672A1 (de) * 2009-02-19 2010-09-02 Johannes-Gutenberg-Universität Mainz Regulatorische Nukleinsäure einer humanen Proteinase 3-Variante
EP3303609A1 (en) * 2015-06-01 2018-04-11 Biogen MA Inc. Assays for evaluating cell culture reagents

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5591427A (en) 1979-10-07 1997-01-07 Medvet Science Pty. Ltd. Human Interleukin-3(Il-3) variants and their use to promote or antagonize IL-3-mediated processes
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0695939B2 (ja) 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE3472793D1 (en) 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide
EP0155549B1 (en) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4717722A (en) 1984-05-07 1988-01-05 Merck & Co., Inc. Substituted 1-oxa-dethiacephalosporins as anti-inflammatory and antidegenerative agents
US4923807A (en) 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
US4797396A (en) 1984-07-02 1989-01-10 Merck & Co., Inc. β-Lactam derivatives as anti-inflammatory and antidegenerative agents
US4711886A (en) 1984-07-02 1987-12-08 Merck & Co., Inc. β-lactam derivatives as anti-inflammatory and antidegenerative agents
GR851626B (no) 1984-07-05 1985-11-26 Genentech Inc
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5109018A (en) 1984-08-20 1992-04-28 Georgia Tech Research Corporation Use of heterocyclic inhibitors of serine proteases
US4596822A (en) 1984-08-20 1986-06-24 Georgia Tech Research Corporation Heterocyclic inhibitors of serine proteases
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
FI853395L (fi) 1984-09-05 1986-03-06 Cetus Corp Monoklonala antikroppar som blockerar gram-negativ bakterieendotoxin.
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5200333A (en) 1985-03-01 1993-04-06 New England Biolabs, Inc. Cloning restriction and modification genes
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4699904A (en) 1985-07-01 1987-10-13 Merck & Co., Inc. Tetrazolyl derivatives of β-lactams useful as elastase inhibitors
JPS62100291A (ja) 1985-10-28 1987-05-09 Teijin Ltd 遺伝子断片およびプラスミド
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0673456B2 (ja) 1986-04-26 1994-09-21 三共株式会社 ヒト・膵臓エラスタ−ゼ▲ｉ▼
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5128258A (en) 1987-01-07 1992-07-07 Board Of Regents, The University Of Texas System Iron-releasing monokines
US4939689A (en) 1987-04-09 1990-07-03 Crowninshield Software, Inc. Outline-driven database editing and retrieval system
US4829054A (en) 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE68927671T2 (de) 1988-12-19 1997-05-07 American Cyanamid Co Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
GB8909810D0 (en) 1989-04-28 1989-06-14 Davy Mckee Stockton Apparatus for probing material in a vessel in a steel production plant
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
JP2930713B2 (ja) 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
US5091303A (en) 1989-10-27 1992-02-25 The General Hospital Corporation Diagnosis of wegener's granulomatosis
US5180819A (en) * 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
DE59106996D1 (de) 1990-06-22 1996-01-11 Jens Luedemann Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände.
JPH05255393A (ja) 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
AU3611093A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones
EP0648225A1 (en) * 1992-06-25 1995-04-19 Chiron Corporation Compositions for the inhibition of protein hormone formation and uses thereof
GB9314350D0 (en) 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives

Also Published As

Publication number Publication date
NO963726L (no) 1996-10-31
US6599706B1 (en) 2003-07-29
WO1995024501A1 (en) 1995-09-14
CA2185162A1 (en) 1995-09-14
EP0749494A1 (en) 1996-12-27
JPH10504441A (ja) 1998-05-06
AU1936495A (en) 1995-09-25
AU709054B2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
GB2302091B (en) Cementing compositions and the application of such compositions to cementing oil or analogous wells
NO180145C (no) Tannbörste og tildannelse av samme
NO982311D0 (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral mukositt
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO940326D0 (no) Sementsammensetninger av fin partikkelstoerrelse og sammensetningsmetode
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
NO971895L (no) Inhibitorer av apolipoprotein <beta>-syntesen
NO961839D0 (no) Biocidpreparater omfattende blandinger av halogenpropynyl-forbindelser og svovelinneholdende triaziner
HK1002432A1 (en) Compositions of difluoromethane and tetrafluoroethane
NO963726D0 (no) Sammensetninger for inhibisjon av TNF-dannelse og anvendelser derav
NO965563D0 (no) Behandling og profylakse av osteoporese
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
NO985214D0 (no) Inhibitorer for produksjon av s-CD23 og sekresjon av TNF
NO20054619D0 (no) Sammensetninger og fremgangsmater for behandling av underjordiske formasjoner
BR9607427A (pt) Inibiçao de angiogêne usando interleucina 12
NO982043D0 (no) Sammensetning av polyisocyanat
DE69610602D1 (de) Antiferroelektrische Flüssigkristallverbindung und antiferroelektrische Flüssigkristallzusammensetzung
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20021832L (no) Farmasöytiske sammensetninger av tizoksanid og nitazoksanid
KR970001458A (ko) 폴리수지와 에폭시- 작용성 폴리올레핀의 조성물
NO180661C (no) Anlegg for å forhindre spredning av fiskebårne parasitter og anvendelse derav
NO952949D0 (no) Forlöpere av anti-inflamatoriske 3-acyl-2-oksindol-1-karboksamider
NO982855D0 (no) Sammensetning av overgangsmetall
GB9613410D0 (en) Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
NO945021D0 (no) Sammensetninger for inhibisjon av proteinhormondannelse og anvendelse derav